Literature DB >> 19561431

A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella.

Anne A Gershon1, Myron J Levin, Adriana Weinberg, Lin-Yee Song, Philip S LaRussa, Sharon P Steinberg, Patterson Bartlett.   

Abstract

Herpes zoster, may be severe and recurrent in HIV-infected children. We determined the safety and immunogenicity of live attenuated varicella-zoster virus (VZV) vaccine in 46 HIV-infected children who had experienced varicella. There were no serious adverse events. Two years after vaccination 82% of subjects remained VZV-antibody positive and 60% had VZV-specific cell-mediated immunity. No child developed herpes zoster.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19561431      PMCID： PMC2868313          DOI： 10.1097/INF.0b013e3181998f06

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  17 in total

1.  Varicella and zoster in children with human immunodeficiency virus infection.

Authors:  A Derryck; P LaRussa; S Steinberg; M Capasso; J Pitt; A A Gershon
Journal:  Pediatr Infect Dis J       Date:  1998-10       Impact factor: 2.129

2.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence.

Authors:  V Williams; A Gershon; P A Brunell
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

3.  Clinical application of responder cell frequency estimates with four years of follow up.

Authors:  A R Hayward; G O Zerbe; M J Levin
Journal:  J Immunol Methods       Date:  1994-03-29       Impact factor: 2.303

4.  Immunization of HIV-infected children with varicella vaccine.

Authors:  M J Levin; A A Gershon; A Weinberg; S Blanchard; B Nowak; P Palumbo; C Y Chan
Journal:  J Pediatr       Date:  2001-08       Impact factor: 4.406

5.  Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection.

Authors:  A A Gershon; N Mervish; P LaRussa; S Steinberg; S H Lo; D Hodes; S Fikrig; V Bonagura; S Bakshi
Journal:  J Infect Dis       Date:  1997-12       Impact factor: 5.226

6.  Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine.

Authors:  Myron J Levin; Jeffrey G Smith; Robin M Kaufhold; Debra Barber; Anthony R Hayward; Christina Y Chan; Ivan S F Chan; David J J Li; William Wang; Paul M Keller; Alan Shaw; Jeffrey L Silber; Katia Schlienger; Ira Chalikonda; S J R Vessey; Michael J Caulfield
Journal:  J Infect Dis       Date:  2003-10-17       Impact factor: 5.226

7.  Immune response of elderly individuals to a live attenuated varicella vaccine.

Authors:  M J Levin; M Murray; H A Rotbart; G O Zerbe; C J White; A R Hayward
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

8.  Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children.

Authors:  Myron J Levin; Jeffrey P Anderson; George R Seage; Paige L Williams
Journal:  J Acquir Immune Defic Syndr       Date:  2009-02-01       Impact factor: 3.731

9.  Frequent recurrence and persistence of varicella-zoster virus infections in children infected with human immunodeficiency virus type 1.

Authors:  L von Seidlein; S G Gillette; Y Bryson; T Frederick; L Mascola; J Church; P Brunell; A Kovacs; A Deveikis; M Keller
Journal:  J Pediatr       Date:  1996-01       Impact factor: 4.406

10.  Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy.

Authors:  Adriana Weinberg; Andrew A Wiznia; Bonnie J LaFleur; Sona Shah; Myron J Levin
Journal:  J Infect Dis       Date:  2004-06-09       Impact factor: 5.226
View more
  9 in total

Review 1.  A literature review on the patients with autoimmune diseases following vaccination against infections.

Authors:  Yan Liang; Fan-Ya Meng; Hai-Feng Pan; Dong-Qing Ye
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.

Authors:  Adriana Weinberg; Ann A Lazar; Gary O Zerbe; Anthony R Hayward; Ivan S F Chan; Rupert Vessey; Jeffrey L Silber; Rob R MacGregor; Kenny Chan; Anne A Gershon; Myron J Levin
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

Review 3.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

4.  Perspectives on vaccines against varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

5.  Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.

Authors:  Jie Zhang; Fenglong Xie; Elizabeth Delzell; Lang Chen; Kevin L Winthrop; James D Lewis; Kenneth G Saag; John W Baddley; Jeffrey R Curtis
Journal:  JAMA       Date:  2012-07-04       Impact factor: 56.272

6.  Immune correlates of herpes zoster in HIV-infected children and youth.

Authors:  Adriana Weinberg; Sharon Huang; Lin-Ye Song; Terry Fenton; Paige Williams; Julie Patterson; Adriana Tovar-Salazar; Myron J Levin
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

7.  The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study.

Authors:  Jie Zhang; Elizabeth Delzell; Fenglong Xie; John W Baddley; Claire Spettell; Raechele M McMahan; Joaquim Fernandes; Lang Chen; Kevin Winthrop; Jeffrey R Curtis
Journal:  Arthritis Res Ther       Date:  2011-10-24       Impact factor: 5.156

Review 8.  Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review.

Authors:  Vincent Muturi-Kioi; David Lewis; Odile Launay; Geert Leroux-Roels; Alessandra Anemona; Pierre Loulergue; Caroline L Bodinham; Annelies Aerssens; Nicola Groth; Allan Saul; Audino Podda
Journal:  PLoS One       Date:  2016-08-04       Impact factor: 3.240

9.  Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.

Authors:  Sinéad M Langan; Liam Smeeth; David J Margolis; Sara L Thomas
Journal:  PLoS Med       Date:  2013-04-09       Impact factor: 11.069
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.